Directory
>
Kevin Fitzgerald
Kevin Fitzgerald
Group Leader | Alnylam Pharmaceuticals
Massachusetts, Brookline, United States
Kevin Fitzgerald
Summary
Kevin Fitzgerald is a highly accomplished biotechnology executive with over 23 years of experience in drug development, particularly focused on patient-centric approaches. As the Chief Scientific Officer at Alnylam Pharmaceuticals, he leads a diverse research team dedicated to pioneering novel drug delivery systems. His expertise spans various areas including oncology, genetics, and orphan disease drug development, and he holds over 50 patents, including those for FDA-approved RNAi therapeutics. Kevin's leadership is characterized by successful collaborations that have generated significant business alliances. He is also a published author in prestigious journals and an engaging public speaker. His academic background includes a Ph.D. from Princeton University and a postdoctoral fellowship at Harvard Medical School, providing him with a solid foundation in genetics and oncology. Kevin's innovative approach and data-driven decision-making have consistently advanced therapeutic discoveries from the lab to clinical application.
Kevin Fitzgerald
Work Experience
Chief Scientific Officer at
Alnylam Pharmaceuticals
December 2018 - Present
Kevin Fitzgerald
Education
Harvard Medical School, Post-Doc, Breast Cancer
January 1995 - January 1998
Princeton University, Ph.D, Biology
January 1989 - January 1995
Cornell University, B.S., Genetics
January 1985 - January 1989
Frequently Asked Questions about Kevin Fitzgerald
What is Kevin Fitzgerald email address?
Kevin Fitzgerald's primary email address is ***********@alnylam.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Kevin Fitzgerald work for?
Kevin Fitzgerald is a Group Leader at Alnylam Pharmaceuticals.
Where Kevin Fitzgerald graduated from?
Kevin Fitzgerald holds a degree in Studied under Dr. Phil Leder (HHMI) Notch, Ras and Wnt signaling pathways. Breast Cancer Mouse Models and Signaling pathways. Transgenic, KO mice, viral models. from Harvard Medical School.
How can I directly contact Kevin Fitzgerald?
To contact Kevin Fitzgerald directly, you can use the email address ***********@alnylam.com. Complete contact information is available upon registration with Muraena.
Who is Kevin Fitzgerald?
Kevin Fitzgerald is a highly accomplished biotechnology executive with over 23 years of experience in drug development, particularly focused on patient-centric approaches. As the Chief Scientific Officer at Alnylam Pharmaceuticals, he leads a diverse research team dedicated to pioneering novel drug delivery systems. His expertise spans various areas including oncology, genetics, and orphan disease drug development, and he holds over 50 patents, including those for FDA-approved RNAi therapeutics. Kevin's leadership is characterized by successful collaborations that have generated significant business alliances. He is also a published author in prestigious journals and an engaging public speaker. His academic background includes a Ph.D. from Princeton University and a postdoctoral fellowship at Harvard Medical School, providing him with a solid foundation in genetics and oncology. Kevin's innovative approach and data-driven decision-making have consistently advanced therapeutic discoveries from the lab to clinical application.
Kevin`s contact details
***********@alnylam.com
***********@attb1.com
Colleagues
Trainee in Pharma Technical Operations
Food & Drug Practice Group, Associate
Associate Scientist, Pharmacology (R&D)
Jr. Product Manager - Anti infectives
Senior Scientist
Regulatory Project Manager
Manufacturing Associate
Cardiologist
Vice President
Medical Science Liaison